September 25–28, 2024, Amsterdam

European Academy of Dermatology and Venereology (EADV)

Poster icon

Remibrutinib-treated patients with CSU who achieve well-controlled disease activity reach this by week 3 in the majority of patients: Results from REMIX-1/-2 studies

Martin Metz, Michihiro Hide, Wei Lai, Sibylle Haemmerle, Nadine Chapman-Rothe, Christine-Elke Ortmann, Giselle Mosnaim
Oral Presentation e-Poster
Poster icon

Efficacy of remibrutinib in patients with CSU by demographics and baseline characteristics: Pooled analysis from REMIX-1 and REMIX-2 studies

Sarbjit Saini, Atsushi Fukunaga, Bin Yang, Sibylle Haemmerle, El-Djouher Martzloff, Christine-Elke Ortmann, Karine Lheritier, Vipul Jain
Oral Presentation e-Poster
Poster icon

REMIX-1/-2: Long-term efficacy of remibrutinib in patients with CSU from the European region

Ana M. Gimenez-Arnau, Knut Brockow, Ansgar Weyergraf, Abdallah Khemis, Christine-Elke Ortmann, Noriko Seko, Pengpeng Wang, Sibylle Haemmerle, Irena Walecka Herniczek
e-Poster
Poster icon

Patient journey and disease burden in chronic inducible urticaria (CIndU): Analysis from the Urticaria Voices study

Sabine Altrichter, Giselle Mosnaim, Jonathan A. Bernstein, Tonya A. Winders, Jessica McCarthy, Pallavi Saraswat, Nadine Chapman-Rothe, Tara Raftery, Karsten Weller
e-Poster
Poster icon

Status update of chronic spontaneous urticaria management and knowledge among Italian GPs: Bridge Implementation Science Study

Piergiacomo Calzavara Pinton, Riccardo Asero, Nadine Chapman-Rothe, Pallavi Saraswat, Vinodh Nallasamy, Abigail Herbst, Bridget Gaglio, Fabio Speranza, Ornella Bonavita, Tara Raftery, Enrico Iemoli
e-Poster
Poster icon

Impact of early vs late biologic treatment initiation on health care resource utilization in patients with chronic spontaneous urticaria: Results from a United States Claims Database Study

Gil Yosipovitch, Dhaval Patil, Merin Kuruvilla, Jason Doran, Irina Pivneva, Frédéric Kinkead, Panagiotis Orfanos, Tara Raftery, Marc A. Riedl
Oral Presentation e-Poster
Poster icon

Variation in CSU management practices between dermatology and immunology/allergy – Results from the REVEAL UK survey

Kashif Bhatti, Michael R Ardern-Jones, Susana Marinho, Tariq El-Shanawany, Suzanne Pilkington, Lauren Bateman, Joe Foggin, Chris Ioannou, Grace Fowler
e-Poster
Poster icon

Epidemiology, clinical characteristics and treatment patterns of chronic spontaneous urticaria patients treated in Finnish secondary care: A register-based study

Emma Heikkinen, Jari Jokelainen, Laura Huilaja, Suvi-Päivikki Sinikumpu, Maija Wolf
e-Poster
Poster icon

Burden of illness in chronic inducible urticaria (CIndU): A targeted literature review (TLR)

Samprati Avasthi, Ravneet Kaur Kohli, Panagiotis Orfanos
e-Poster
Poster icon

Early and long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria: 52-week data from the Phase 3 REMIX-1 and REMIX-2 studies

A.M. Giménez-Arnau, M. Metz, M. Hide, V. Jain, A. Khemis, M. Lebwohl, M. Palumbo, S. Saini, E. Şavk, G. Sussman, R. Szalewski, I.W. Herniczek, H. Windom, B. Yang, S. Haemmerle, K. Lheritier, Paula G.P. Machado, E-D. Martzloff, N. Seko, P. Wang, A. Zharkov, M. Maurer
Oral Presentation
Poster icon

Effect of remibrutinib treatment on disease activity in chronic spontaneous urticaria: Data from the Phase 3 REMIX-1 and
REMIX-2 studies

M. Metz, S. Saini, F. Berard, J. Reed, M. Maurer, S. Altrichter, C-Y. Chu, B. Suryawanshi, C-E. Ortmann, N. Chapman-Rothe, S. Haemmerle, J. Kern
e-Poster
Poster icon

CSU disease activity band shift after long-term treatment with remibrutinib in the Phase 3 REMIX-1 & REMIX-2 studies

M. Metz, A. M. Giménez-Arnau, P. Staubach, M.F. Puga, K. Kulthanan, X-H. Gao, K. Lheritier, C-E. Ortmann, N. Chapman-Rothe, S. Haemmerle, A. Fukunaga, M. Hide
e-Poster
Poster icon

Impact of remibrutinib on Dermatology-Related Quality of Life (DLQI) in patients with chronic spontaneous urticaria in the Phase 3 REMIX-1 and REMIX-2 studies

J. Reed, M. Metz, R. Saini, R. Szalewski, M. Lebwohl, M. Maurer, G. Sussman, S. Haemmerle, N. Seko, P. Wang, C. Field, M. J. Palumbo
e-Poster
Poster icon

Impact of chronic spontaneous urticaria on health-related quality of life domains: Country-specific data from patients participating in the Urticaria Voices study

T. A. Winders, J.A. Bernstein, J. McCarthy, P. Saraswat, N. Chapman-Rothe, T. Raftery, K. Weller
e-Poster
Poster icon

Physicians' perspective on the burden of CSU for patients and unmet need while treating CSU: Country-wide data from Urticaria Voices

J. A. Bernstein, T. A. Winders, J. McCarthy, P. Saraswat, N. Chapman-Rothe, T. Raftery, K. Weller
e-Poster
Poster icon

Utility scores in chronic spontaneous urticaria: A systematic literature review and statistical analysis

R. Kohli, E. Hawe, S. Harold, E. Simou, A. Chrysos, P. Orfanos
e-Poster
Novartis logo
Cookie Settings
© Copyright 2025 Novartis Pharma AG